Forward view – our priority topics for 2026 to 2027
Our forward view highlights the areas we will prioritise in the coming year.
These topics will be refreshed on an annual basis. We may also update them during the year in response to major developments or new innovations in the life sciences, health and care sectors.
Prioritising topics that matter most
Our mission is to get the best care to people fast, while ensuring value for the taxpayer.
Prioritising the topics we produce guidance for is essential so that we know we're focusing on the areas that matter most to you in the health and social care system.
During the 2025 to 2026 business year, we'll be focusing on:
Guidance in development
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
Artificial Intelligence assisted Echocardiography to support diagnosis of heart failure
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)
Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623].
Guidance awaiting development
Interventional procedures guidance
Guidance in development
Guidance in development
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
Total hip arthroplasty using the superpath approach for osteoarthritis
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy [ID6556]
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195].